Angimmune LLC - Developer of Resimmune™, an Anti-T Cell Immunotoxin

T cell Targeting for Cancer, Autoimmune Disease, and Induction Immunotherapy

A New Method to Induce Immunomodulation

A-dmDT390-bisFv(UCHT1).

Resimmune® is an Anti-CD3 Immunotoxin that can be used to induce anti-tumor CD8+ central memory T cell expansion following T cell depletion during Homeostatic Proliferation.
CD8+ central memory T cells increase 20 fold by day 16 during homeostatic proliferation in the absence of antigen exposure, yet acquire effector functions. Normally they revert to naïve T cells following repopulation of the T cell compartment and lose effector functions.
When homeostatic proliferation is combined with tumor lysis and the release of tumor antigens, anti-tumor immune responses appear to persist 2-3 years in cutaneous T cell lymphoma as judged by clinical outcomes (see Clinical Response Over Time chart).

Applications & Advantages

The therapy has potential application for T cell blood cancers, T cell driven autoimmune diseases, Immuno-oncology, and as a transplantation induction immunotherapy that prevents antibody mediated rejection through B-cell tolerance. Resimmune^® is also being investigated as an immunomodulator in combination with checkpoint inhibitors. With the drug administered in four days versus multiple courses of other treatments, the drug has the potential to reduce both treatment time and expense. Resimmune^® has been granted Orphan Drug Designation and FDA Fast Track Development Designation for the treatment of Cutaneous T-Cell Lymphoma (CTCL).

Translation of a Novel Induction Therapy for Transplantation to Prevent Antibody Mediated Rejection

According to the CDC, in 2016, nearly 125,000 people in the United States started treatment for end-stage kidney disease, and more than 726,000 (2 in every 1,000 people) were on dialysis or were living with a kidney transplant. There are approximately 113,759 patients currently on the kidney transplant wait list, and this list is growing exponentially. Antibody mediated rejection is the leading cause of graft loss after kidney transplantation. Research in preclinical large animal models with analogs to Angimmune’s human anti-CD3 rIT has led to the discovery of a novel, clinically relevant, therapeutic strategy for prevention of antibody mediated rejection following organ transplantation through the induction of stable B-cell tolerance. Unpublished animal data suggests that the unique properties of CD3 immunotoxin contribute to an immune regulatory response when combined with a proprietary transplantation induction protocol, resulting in stable B-cell tolerance induction. Angimmune is working in conjunction with these researchers on developing a clinical protocol to prevent antibody-mediated rejection post kidney transplantation. There are approximately 22,000 transplants performed each year in the U.S. and the majority of these patients would be eligible for this protocol. If shown promise in the setting for kidney transplantation, there is potential to extend this innovation as induction therapy for all types of organ transplants performed.

Licensing & Collaboration

Angimmune welcomes inquiries regarding licensing and collaboration with our technology. Our high potency DT390 Pichia platform can accept a wide variety of proprietary antibody sequences produced with Bivalent binding for increased affinity and internalization to targeted cells.